It has been shown that HER2 overexpression may have a role in developing resistance to the aromatoase inhibitor letrozole and that tumours relapsing early while on adjuvant tamoxifen therapy exhibit high levels of HER2 protein and/or gene amplification (Shin et al, 2006). The gene discussed is ERBB2; the disease is neoplasm.